;PMID: 1913654
;source_file_811.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..129] = [t:42..129]
;2)section:[e:133..206] = [t:133..206]
;3)section:[e:210..350] = [t:210..350]
;4)sentence:[e:354..565] = [t:354..565]
;5)sentence:[e:566..903] = [t:566..903]
;6)sentence:[e:905..1018] = [t:905..1018]
;7)sentence:[e:1019..1177] = [t:1019..1177]
;8)sentence:[e:1178..1251] = [t:1178..1251]
;9)sentence:[e:1252..1352] = [t:1252..1352]
;10)sentence:[e:1353..1451] = [t:1353..1451]
;11)sentence:[e:1452..1532] = [t:1452..1532]
;12)sentence:[e:1533..1702] = [t:1533..1702]
;13)sentence:[e:1703..1899] = [t:1703..1899]
;14)sentence:[e:1900..2065] = [t:1900..2065]
;15)sentence:[e:2066..2147] = [t:2066..2147]
;16)section:[e:2151..2195] = [t:2151..2195]

;section 0 Span:0..37
;Cancer Res  1991 Oct 1;51(19):5308-14
(SEC
  (FRAG (NN:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 1991)
        (IN:[17..20] Oct) (CD:[21..26] 1;51-LRB-) (CD:[26..28] 19)
        (-RRB-:[28..29] -RRB-) (CD:[29..34] :5308) (::[34..35] -)
        (CD:[35..37] 14)))

;sentence 1 Span:42..129
;K-ras activation in premalignant and malignant epithelial lesions of the
;human  uterus.
;[42..47]:gene-rna:"K-ras"
;[62..74]:malignancy:"premalignant"
;[79..128]:malignancy:"malignant epithelial lesions of the human  uterus"
(SENT
  (NP-HLN
    (NP (NN:[42..47] K-ras) (NN:[48..58] activation))
    (PP (IN:[59..61] in)
      (NP
        (NP
          (NP (JJ:[62..74] premalignant)
            (NML-1 (-NONE-:[74..74] *P*)))
          (CC:[75..78] and)
          (NP (JJ:[79..88] malignant)
            (NML-1 (JJ:[89..99] epithelial) (NNS:[100..107] lesions))))
        (PP (IN:[108..110] of)
          (NP (DT:[111..114] the) (JJ:[115..120] human) (NN:[122..128] uterus)))))
    (.:[128..129] .)))

;section 2 Span:133..206
;Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, Rice JM.
(SEC
  (FRAG (NNP:[133..140] Enomoto) (NNP:[141..142] T) (,:[142..143] ,)
        (NNP:[144..149] Inoue) (NNP:[150..152] M,) (NNP:[153..162] Perantoni)
        (NNP:[163..165] AO) (,:[165..166] ,) (NNP:[167..173] Buzard)
        (NNP:[174..176] GS) (,:[176..177] ,) (NNP:[178..182] Miki)
        (NNP:[183..184] H) (,:[184..185] ,) (NNP:[186..194] Tanizawa)
        (NNP:[195..196] O) (,:[196..197] ,) (NNP:[198..202] Rice)
        (NNPS:[203..205] JM) (.:[205..206] .)))

;section 3 Span:210..350
;Laboratory of Comparative Carcinogenesis, National Cancer Institute,
;Frederick  Cancer Research and Development Center, Maryland 21702-1201.
(SEC
  (FRAG (NN:[210..220] Laboratory) (IN:[221..223] of)
        (NNP:[224..235] Comparative) (NNP:[236..250] Carcinogenesis)
        (,:[250..251] ,) (NNP:[252..260] National) (NNP:[261..267] Cancer)
        (NNP:[268..277] Institute) (,:[277..278] ,) (NNP:[279..288] Frederick)
        (NNP:[290..296] Cancer) (NNP:[297..305] Research) (CC:[306..309] and)
        (NNP:[310..321] Development) (NNP:[322..328] Center) (,:[328..329] ,)
        (NNP:[330..338] Maryland) (CD:[339..344] 21702) (::[344..345] -)
        (CD:[345..349] 1201) (.:[349..350] .)))

;sentence 4 Span:354..565
;We previously reported (Cancer Res., 50:6139-6145, 1990) a significant
;frequency  of activating point mutations in codon 12 of the K-ras oncogene in
;endometrial  adenocarcinomas of the uterine corpus (series 1).
;[450..465]:variation-type:"point mutations"
;[469..477]:variation-location:"codon 12"
;[485..490]:gene-rna:"K-ras"
;[503..553]:malignancy:"endometrial  adenocarcinomas of the uterine corpus"
(SENT
  (S
    (NP-SBJ (PRP:[354..356] We))
    (ADVP-TMP (RB:[357..367] previously))
    (VP (VBD:[368..376] reported)
      (PRN (-LRB-:[377..378] -LRB-)
        (FRAG (NNP:[378..384] Cancer) (NNP:[385..389] Res.) (,:[389..390] ,)
              (CD:[391..393] 50) (::[393..394] :) (CD:[394..398] 6139)
              (HYPH:[398..399] -) (CD:[399..403] 6145) (,:[403..404] ,)
              (CD:[405..409] 1990))
        (-RRB-:[409..410] -RRB-))
      (NP
        (NP (DT:[411..412] a) (JJ:[413..424] significant)
            (NN:[425..434] frequency))
        (PP (IN:[436..438] of)
          (NP
            (NP (VBG:[439..449] activating)
               (NN:[450..455] point) (NNS:[456..465] mutations))
            (PP-LOC (IN:[466..468] in)
              (NP
                (NP (NN:[469..474] codon) (CD:[475..477] 12))
                (PP (IN:[478..480] of)
                  (NP (DT:[481..484] the) (NN:[485..490] K-ras)
                      (NN:[491..499] oncogene)))))
            (PP-LOC (IN:[500..502] in)
              (NP
                (NP (JJ:[503..514] endometrial) (NNS:[516..531] adenocarcinomas))
                (PP (IN:[532..534] of)
                  (NP (DT:[535..538] the) (JJ:[539..546] uterine)
                      (NN:[547..553] corpus)
                    (PRN (-LRB-:[554..555] -LRB-)
                      (NP
                        (NML (NN:[555..561] series))
                        (CD:[562..563] 1))
                      (-RRB-:[563..564] -RRB-))))))))))
    (.:[564..565] .)))

;sentence 5 Span:566..903
;To further define the role of  ras activation in the development of
;endometrial adenocarcinoma, we surveyed  cystic, adenomatous, and atypical
;hyperplasias of uterine endometrium and  additional cases of endometrial and
;cervical carcinoma (series 2) for the  presence of activating mutations in
;cellular protooncogenes of the ras family.
;[597..600]:gene-rna:"ras"
;[634..660]:malignancy:"endometrial adenocarcinoma"
;[675..681]:malignancy:"cystic"
;[683..694]:malignancy:"adenomatous"
;[700..744]:malignancy:"atypical hyperplasias of uterine endometrium"
;[770..804]:malignancy:"endometrial and cervical carcinoma"
;[848..857]:variation-event:"mutations"
;[892..895]:gene-rna:"ras"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[566..566] *))
      (VP (TO:[566..568] To)
        (ADVP (RB:[569..576] further))
        (VP (VB:[577..583] define)
          (NP
            (NP (DT:[584..587] the) (NN:[588..592] role))
            (PP (IN:[593..595] of)
              (NP (NN:[597..600] ras) (NN:[601..611] activation))))
          (PP (IN:[612..614] in)
            (NP
              (NP (DT:[615..618] the) (NN:[619..630] development))
              (PP (IN:[631..633] of)
                (NP (JJ:[634..645] endometrial) (NN:[646..660] adenocarcinoma))))))))
    (,:[660..661] ,)
    (NP-SBJ (PRP:[662..664] we))
    (VP (VBD:[665..673] surveyed)
      (NP
        (NP
          (NP
            (NP (JJ:[675..681] cystic)
              (NML-1 (-NONE-:[681..681] *P*)))
            (,:[681..682] ,)
            (NP (JJ:[683..694] adenomatous)
              (NML-1 (-NONE-:[694..694] *P*)))
            (,:[694..695] ,) (CC:[696..699] and)
            (NP (JJ:[700..708] atypical)
              (NML-1 (NNS:[709..721] hyperplasias))))
          (PP (IN:[722..724] of)
            (NP (JJ:[725..732] uterine) (NN:[733..744] endometrium))))
        (CC:[745..748] and)
        (NP
          (NP (JJ:[750..760] additional) (NNS:[761..766] cases))
          (PP (IN:[767..769] of)
            (NP
              (NP (JJ:[770..781] endometrial)
                (NML-2 (-NONE-:[781..781] *P*)))
              (CC:[782..785] and)
              (NP (JJ:[786..794] cervical)
                (NML-2 (NN:[795..804] carcinoma))
                (PRN (-LRB-:[805..806] -LRB-) (NN:[806..812] series)
                     (CD:[813..814] 2) (-RRB-:[814..815] -RRB-)))))))
      (PP (IN:[816..819] for)
        (NP
          (NP (DT:[820..823] the) (NN:[825..833] presence))
          (PP (IN:[834..836] of)
            (NP
              (NP (VBG:[837..847] activating) (NNS:[848..857] mutations))
              (PP-LOC (IN:[858..860] in)
                (NP
                  (NP (JJ:[861..869] cellular) (NNS:[870..884] protooncogenes))
                  (PP (IN:[885..887] of)
                    (NP (DT:[888..891] the) (NN:[892..895] ras)
                        (NN:[896..902] family))))))))))
    (.:[902..903] .)))

;sentence 6 Span:905..1018
;Polymerase chain reaction was performed from deparaffinized sections of 
;formalin-fixed paraffin-embedded tissue.
;[905..915]:gene-protein:"Polymerase"
(SENT
  (S
    (NP-SBJ-1 (NN:[905..915] Polymerase) (NN:[916..921] chain)
              (NN:[922..930] reaction))
    (VP (VBD:[931..934] was)
      (VP (VBN:[935..944] performed)
        (NP-1 (-NONE-:[944..944] *))
        (PP (IN:[945..949] from)
          (NP
            (NP (VBN:[950..964] deparaffinized) (NNS:[965..973] sections))
            (PP (IN:[974..976] of)
              (NP
                (ADJP
                  (ADJP (NN:[978..986] formalin) (HYPH:[986..987] -)
                        (VBN:[987..992] fixed))
                  (ADJP (NN:[993..1001] paraffin) (HYPH:[1001..1002] -)
                        (VBN:[1002..1010] embedded)))
                (NN:[1011..1017] tissue)))))))
    (.:[1017..1018] .)))

;sentence 7 Span:1019..1177
;We screened for point mutations in  codons 12, 13, and 61 of the K-, H-, and
;N-ras genes by dot blot hybridization  analysis with mutation-specific
;oligomers.
;[1035..1050]:variation-type:"point mutations"
;[1055..1064]:variation-location:"codons 12"
;[1055..1061]...[1074..1076]:variation-location:"codons"..."61"
;[1055..1061]...[1066..1068]:variation-location:"codons"..."13"
;[1084..1086]...[1098..1101]:gene-rna:"K-"..."ras"
;[1088..1090]...[1098..1101]:gene-rna:"H-"..."ras"
;[1096..1101]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ (PRP:[1019..1021] We))
    (VP (VBD:[1022..1030] screened)
      (PP (IN:[1031..1034] for)
        (NP
          (NP (NN:[1035..1040] point) (NNS:[1041..1050] mutations))
          (PP-LOC (IN:[1051..1053] in)
            (NP
              (NP
                (NP
                  (NML-1 (NNS:[1055..1061] codons))
                  (CD:[1062..1064] 12))
                (,:[1064..1065] ,)
                (NP
                  (NML-1 (-NONE-:[1065..1065] *P*))
                  (CD:[1066..1068] 13))
                (,:[1068..1069] ,) (CC:[1070..1073] and)
                (NP
                  (NML-1 (-NONE-:[1073..1073] *P*))
                  (CD:[1074..1076] 61)))
              (PP (IN:[1077..1079] of)
                (NP (DT:[1080..1083] the)
                  (NML
                    (NML
                      (NML (NN:[1084..1085] K) (HYPH:[1085..1086] -)
                        (NML-2 (-NONE-:[1086..1086] *P*)))
                      (NML-3 (-NONE-:[1086..1086] *P*)))
                    (,:[1086..1087] ,)
                    (NML
                      (NML (NN:[1088..1089] H) (HYPH:[1089..1090] -)
                        (NML-2 (-NONE-:[1090..1090] *P*)))
                      (NML-3 (-NONE-:[1090..1090] *P*)))
                    (,:[1090..1091] ,) (CC:[1092..1095] and)
                    (NML
                      (NML (NN:[1096..1097] N) (HYPH:[1097..1098] -)
                        (NML-2 (NN:[1098..1101] ras)))
                      (NML-3 (NNS:[1102..1107] genes))))))))))
      (PP-MNR (IN:[1108..1110] by)
        (NP
          (NP
            (NML (NN:[1111..1114] dot) (NN:[1115..1119] blot))
            (NN:[1120..1133] hybridization) (NN:[1135..1143] analysis))
          (PP (IN:[1144..1148] with)
            (NP
              (ADJP (NN:[1149..1157] mutation) (HYPH:[1157..1158] -)
                    (JJ:[1158..1166] specific))
              (NNS:[1167..1176] oligomers))))))
    (.:[1176..1177] .)))

;sentence 8 Span:1178..1251
;Mutations in K-ras were also  confirmed by direct genomic DNA sequencing.
;[1191..1196]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[1178..1187] Mutations))
      (PP-LOC (IN:[1188..1190] in)
        (NP (NN:[1191..1196] K-ras))))
    (VP (VBD:[1197..1201] were)
      (ADVP (RB:[1202..1206] also))
      (VP (VBN:[1208..1217] confirmed)
        (NP-1 (-NONE-:[1217..1217] *))
        (PP-MNR (IN:[1218..1220] by)
          (NP (JJ:[1221..1227] direct) (JJ:[1228..1235] genomic)
              (NN:[1236..1239] DNA) (NN:[1240..1250] sequencing)))))
    (.:[1250..1251] .)))

;sentence 9 Span:1252..1352
;Of 19 endometrial adenocarcinomas in  series 2, point mutations in ras genes
;were found in 7 tumors.
;[1258..1285]:malignancy:"endometrial adenocarcinomas"
;[1300..1315]:variation-type:"point mutations"
;[1319..1322]:gene-rna:"ras"
;[1345..1351]:malignancy:"tumors"
(SENT
  (S
    (PP (IN:[1252..1254] Of)
      (NP
        (NP (CD:[1255..1257] 19)
           (JJ:[1258..1269] endometrial) (NNS:[1270..1285] adenocarcinomas))
        (PP (IN:[1286..1288] in)
          (NP (NN:[1290..1296] series) (CD:[1297..1298] 2)))))
    (,:[1298..1299] ,)
    (NP-SBJ-1
      (NP (NN:[1300..1305] point) (NNS:[1306..1315] mutations))
      (PP-LOC (IN:[1316..1318] in)
        (NP (NN:[1319..1322] ras) (NNS:[1323..1328] genes))))
    (VP (VBD:[1329..1333] were)
      (VP (VBN:[1334..1339] found)
        (NP-1 (-NONE-:[1339..1339] *))
        (PP (IN:[1340..1342] in)
          (NP (CD:[1343..1344] 7) (NNS:[1345..1351] tumors)))))
    (.:[1351..1352] .)))

;sentence 10 Span:1353..1451
;Six contained  single-base substitutions, five in codon 12 of K-ras and one
;in codon 12 of  N-ras.
;[1368..1393]:variation-type:"single-base substitutions"
;[1403..1411]:variation-location:"codon 12"
;[1415..1420]:gene-rna:"K-ras"
;[1432..1440]:variation-location:"codon 12"
;[1445..1450]:gene-rna:"N-ras"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1353..1356] Six))
      (NP-1 (-NONE-:[1356..1356] *ICH*)))
    (VP (VBD:[1357..1366] contained)
      (NP (JJ:[1368..1379] single-base) (NNS:[1380..1393] substitutions))
      (,:[1393..1394] ,)
      (NP-1
        (NP
          (NP (CD:[1395..1399] five))
          (PP-LOC (IN:[1400..1402] in)
            (NP
              (NP (NN:[1403..1408] codon) (CD:[1409..1411] 12))
              (PP (IN:[1412..1414] of)
                (NP (NN:[1415..1420] K-ras))))))
        (CC:[1421..1424] and)
        (NP
          (NP (CD:[1425..1428] one))
          (PP-LOC (IN:[1429..1431] in)
            (NP
              (NP (NN:[1432..1437] codon) (CD:[1438..1440] 12))
              (PP (IN:[1441..1443] of)
                (NP (NN:[1445..1450] N-ras))))))))
    (.:[1450..1451] .)))

;sentence 11 Span:1452..1532
;The seventh tumor contained two different point mutations in codon 12 of 
;K-ras.
;[1464..1469]:malignancy:"tumor"
;[1494..1509]:variation-type:"point mutations"
;[1513..1521]:variation-location:"codon 12"
;[1526..1531]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ (DT:[1452..1455] The) (JJ:[1456..1463] seventh)
            (NN:[1464..1469] tumor))
    (VP (VBD:[1470..1479] contained)
      (NP (CD:[1480..1483] two) (JJ:[1484..1493] different)
         (NN:[1494..1499] point) (NNS:[1500..1509] mutations))
      (PP-LOC (IN:[1510..1512] in)
        (NP
          (NP (NN:[1513..1518] codon) (CD:[1519..1521] 12))
          (PP (IN:[1522..1524] of)
            (NP (NN:[1526..1531] K-ras))))))
    (.:[1531..1532] .)))

;sentence 12 Span:1533..1702
;In one endometrial adenocarcinoma, tumor cells with point mutations in  K-ras
;were predominantly localized to a portion that had a more aggressive 
;histological pattern.
;[1540..1566]:malignancy:"endometrial adenocarcinoma"
;[1568..1579]:malignancy:"tumor cells"
;[1585..1600]:variation-type:"point mutations"
;[1605..1610]:gene-rna:"K-ras"
(SENT
  (S
    (PP-LOC (IN:[1533..1535] In)
      (NP (CD:[1536..1539] one)
         (JJ:[1540..1551] endometrial) (NN:[1552..1566] adenocarcinoma)))
    (,:[1566..1567] ,)
    (NP-SBJ-1
      (NP (NN:[1568..1573] tumor) (NNS:[1574..1579] cells))
      (PP (IN:[1580..1584] with)
        (NP
          (NP (NN:[1585..1590] point) (NNS:[1591..1600] mutations))
          (PP (IN:[1601..1603] in)
            (NP (NN:[1605..1610] K-ras))))))
    (VP (VBD:[1611..1615] were)
      (ADVP (RB:[1616..1629] predominantly))
      (VP (VBN:[1630..1639] localized)
        (NP-1 (-NONE-:[1639..1639] *))
        (PP (TO:[1640..1642] to)
          (NP
            (NP (DT:[1643..1644] a) (NN:[1645..1652] portion))
            (SBAR
              (WHNP-2 (WDT:[1653..1657] that))
              (S
                (NP-SBJ-2 (-NONE-:[1657..1657] *T*))
                (VP (VBD:[1658..1661] had)
                  (NP (DT:[1662..1663] a)
                    (ADJP (RBR:[1664..1668] more) (JJ:[1669..1679] aggressive))
                    (JJ:[1681..1693] histological) (NN:[1694..1701] pattern)))))))))
    (.:[1701..1702] .)))

;sentence 13 Span:1703..1899
;In endometrial hyperplasia, K-ras mutations, one in codon  12 and one in
;codon 13, were found in 2 of 16 hyperplasias histologically  classified as
;atypical and clinically considered premalignant.
;[1706..1729]:malignancy:"endometrial hyperplasia"
;[1731..1736]:gene-rna:"K-ras"
;[1737..1746]:variation-event:"mutations"
;[1755..1764]:variation-location:"codon  12"
;[1776..1784]:variation-location:"codon 13"
;[1808..1898]:malignancy:"hyperplasias histologically  classified as atypical
;and clinically considered premalignant"
(SENT
  (S
    (PP (IN:[1703..1705] In)
      (NP (JJ:[1706..1717] endometrial) (NN:[1718..1729] hyperplasia)))
    (,:[1729..1730] ,)
    (NP-SBJ-1
      (NP (NN:[1731..1736] K-ras) (NNS:[1737..1746] mutations))
      (,:[1746..1747] ,)
      (NP
        (NP
          (NP (CD:[1748..1751] one))
          (PP-LOC (IN:[1752..1754] in)
            (NP (NN:[1755..1760] codon) (CD:[1762..1764] 12))))
        (CC:[1765..1768] and)
        (NP
          (NP (CD:[1769..1772] one))
          (PP-LOC (IN:[1773..1775] in)
            (NP (NN:[1776..1781] codon) (CD:[1782..1784] 13))))))
    (,:[1784..1785] ,)
    (VP (VBD:[1786..1790] were)
      (VP (VBN:[1791..1796] found)
        (NP-1 (-NONE-:[1796..1796] *))
        (PP-LOC (IN:[1797..1799] in)
          (NP
            (NP (CD:[1800..1801] 2))
            (PP (IN:[1802..1804] of)
              (NP
                (NP (CD:[1805..1807] 16) (NNS:[1808..1820] hyperplasias))
                (VP
                  (VP
                    (ADVP (RB:[1821..1835] histologically))
                    (VBN:[1837..1847] classified)
                    (NP (-NONE-:[1847..1847] *))
                    (PP-CLR (IN:[1848..1850] as)
                      (NP (JJ:[1851..1859] atypical))))
                  (CC:[1860..1863] and)
                  (VP
                    (ADVP (RB:[1864..1874] clinically))
                    (VBN:[1875..1885] considered)
                    (S
                      (NP-SBJ (-NONE-:[1885..1885] *))
                      (ADJP-PRD (JJ:[1886..1898] premalignant)))))))))))
    (.:[1898..1899] .)))

;sentence 14 Span:1900..2065
;None of 6  adenomatous hyperplasias and none of 12 cystic hyperplasias, the
;latter of which  is considered clinically benign, contained any detectable
;ras mutations.
;[1911..1935]:malignancy:"adenomatous hyperplasias"
;[1951..1970]:malignancy:"cystic hyperplasias"
;[2051..2054]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[1900..1904] None))
        (PP (IN:[1905..1907] of)
          (NP (CD:[1908..1909] 6)
             (JJ:[1911..1922] adenomatous) (NNS:[1923..1935] hyperplasias))))
      (CC:[1936..1939] and)
      (NP
        (NP (NN:[1940..1944] none))
        (PP (IN:[1945..1947] of)
          (NP (CD:[1948..1950] 12)
             (JJ:[1951..1957] cystic) (NNS:[1958..1970] hyperplasias)))))
    (,:[1970..1971] ,)
    (NP-ADV
      (NP (DT:[1972..1975] the) (JJ:[1976..1982] latter))
      (PP (IN:[1983..1985] of)
        (SBAR
          (WHNP-1 (WDT:[1986..1991] which))
          (S
            (NP-SBJ-1 (-NONE-:[1991..1991] *T*))
            (VP (VBZ:[1993..1995] is)
              (VP (VBN:[1996..2006] considered)
                (S
                  (NP-SBJ-1 (-NONE-:[2006..2006] *))
                  (ADJP-PRD (RB:[2007..2017] clinically)
                            (JJ:[2018..2024] benign)))))))))
    (,:[2024..2025] ,)
    (VP (VBD:[2026..2035] contained)
      (NP (DT:[2036..2039] any) (JJ:[2040..2050] detectable)
          (NN:[2051..2054] ras) (NNS:[2055..2064] mutations)))
    (.:[2064..2065] .)))

;sentence 15 Span:2066..2147
;No  mutations in H-ras were detected in either carcinomas or hyperplastic
;tissue.
;[2083..2088]:gene-rna:"H-ras"
;[2113..2123]:malignancy:"carcinomas"
;[2127..2146]:malignancy:"hyperplastic tissue"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[2066..2068] No) (NNS:[2070..2079] mutations))
      (PP (IN:[2080..2082] in)
        (NP (NN:[2083..2088] H-ras))))
    (VP (VBD:[2089..2093] were)
      (VP (VBN:[2094..2102] detected)
        (NP-1 (-NONE-:[2102..2102] *))
        (PP-LOC (IN:[2103..2105] in)
          (NP (CC:[2106..2112] either)
            (NP (NNS:[2113..2123] carcinomas))
            (CC:[2124..2126] or)
            (NP (JJ:[2127..2139] hyperplastic) (NN:[2140..2146] tissue))))))
    (.:[2146..2147] .)))

;section 16 Span:2151..2195
;PMID: 1913654 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2151..2155] PMID) (::[2155..2156] :) (CD:[2157..2164] 1913654)
        (NN:[2165..2166] -LSB-) (NNP:[2166..2172] PubMed) (::[2173..2174] -)
        (NN:[2175..2182] indexed) (IN:[2183..2186] for)
        (NNP:[2187..2195] MEDLINE-RSB-)))
